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Abstract 
Background: As the population ages and cancer therapies improve, there is an increased call for elderly cancer 
patients to be admitted to the intensive care unit (ICU). This study aimed to assess short‑term survival and prognostic 
factors in critically ill patients with solid tumors aged ≥65 years.
Methods: We conducted a retrospective study. The primary endpoint was ICU mortality. Resumption of anticancer 
therapy in patients who survived the ICU stay and 90‑day mortality were secondary endpoints. All patients aged 
≥65 years admitted to the ICU of Georges Pompidou Hospital (Paris, France) between 2009 and 2014 were eligible.
Results: Of 2327 eligible elderly patients (EP), 262 (75.0 ± 6.7 years) with solid tumors were analyzed. These patients 
were extremely critically ill (SAPS 2 61.9 ± 22.5), and 60.3% had metastatic disease. Gastrointestinal, lung and genitou‑
rinary cancers were the most common types of tumors. Mechanical ventilation was required in 51.5% of patients, ino‑
tropes in 48.1% and dialysis in 12.6%. Most patients (66.7%) were admitted for reasons unrelated to cancer, including 
sepsis (30.5%), acute respiratory failure (28.2%) and neurological problems (8.0%). ICU mortality in patients with cancer 
was 33.6 versus 32.6% among patients without cancer (p = 0.75). Among the cancer EP, the 90‑day mortality was 
51.9% (n = 136). In multivariate analysis, increased SAPS 2 score and primary tumor site were associated with 90‑day 
death, whereas previous anticancer therapies and poor performance status were not. Among survivor patients from 
ICU with anti‑tumoral treatment indication, 77 (52.7%) had resumption of anticancer treatment.
Conclusions: Elderly solid tumor patients admitted to the ICU had a mortality rate similar to EP without cancer. 
Prognostic factors for 90‑day mortality were more related to severity of clinical status at admission than the presence 
or stage of cancer, suggesting that early admission of EP with cancer to the ICU is appropriate.
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Background
Cancer is the leading cause of mortality in France, ahead 
of cardiovascular diseases. In 2015 there were 385,000 
new cases of cancer in France, with 149,500 cancer-
related deaths [1]. The median age at diagnosis of can-
cer is 65 years, and the rate of cancer diagnosis increases 
with age in both males and females [2].
Remarkable advances have been made in the early diag-
nosis and management of patients with malignancies, 
resulting in dramatic improvements in overall survival 
rates [3, 4]. As a result, increasing numbers of oncology 
patients are admitted to the intensive care unit (ICU), 
for either life-threatening cancer-related complications, 
treatment-associated side effects or standard critical care 
admission indications [5].
Overall, survival rates in critically ill patients with 
active cancer appear to be increasing [5]. However, 
studies conducted among patients with hematological 
malignancies or lung cancer indicate that ICU mortality 
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in these patients is high [6–8]. In addition, a number of 
unanswered questions remain, including a lack of follow-
up data on patients who survive a stay in ICU, and data 
on the clinical course and anticancer treatment continu-
ation rates after the critical illness are very limited [8, 9]. 
Furthermore, there is a lack of data on ICU patients with 
non-hematological malignancies.
The aim of this study was to assess patient outcomes 
and identify factors associated with 90-day mortality and 
antineoplastic treatment resumption in elderly patients 




This retrospective observational study was conducted 
between 2009 and 2014 in the ICU of the European 
Georges Pompidou Hospital (Paris, France). The proto-
col was approved by the local institutional ethics com-
mittee, and the study was performed in accordance with 
the ethical standards laid down in the 1964 Declaration 
of Helsinki.
Patients
Consecutive patients were eligible for inclusion if they 
were aged 65 years or older, with or without a diagnosis 
of malignant solid tumor. Patients with hematological 
malignancy, an ICU stay of <24 h with limitation of active 
therapies, cancer diagnosed during the ICU stay, or can-
cer remission of more than 5 years were excluded.
Data collection
Data were collected retrospectively from patients’ com-
puterized medical files using the Dxcare software. Demo-
graphic data, performance status, cancer data (primary 
tumor, presence of metastases, metastatic sites, number 
of previous anticancer treatments, type of treatment and 
neutropenia status), reasons for ICU admission, status at 
admission assessed using the SAPS 2 score [10], life-sup-
port therapies used and the duration of use (mechanical 
ventilation, inotropes), and biological data at admission 
were collected. Reasons for admission were classified in 
two ways: one based on relationship with cancer (related 
to cancer progression or antineoplastic treatment tox-
icity, or no link with cancer) and the second based on 
medical diagnosis at admission (sepsis, acute heart fail-
ure, hemorrhagic shock, hypovolemia, acute respiratory 
failure, chronic bronchitis exacerbation, neurological 
reasons (i.e., coma and/or seizure), acute kidney failure, 
electrolytic disorders, cardiorespiratory shock, post-sur-
gery, medical surveillance, unknown shock). The reason 
for admission was considered as the symptom at the ori-
gin of the ICU request.
Outcomes
ICU mortality rates were determined for elderly patients 
with and without solid tumors. For those with solid 
tumors, in-hospital mortality, 90-day mortality and anti-
cancer treatment resumption were also assessed.
Statistical analysis
Statistical analysis was performed using R software. For 
quantitative variables, mean and standard deviations 
were calculated. Discrete variables are presented as per-
centages. Comparisons between patient characteristics 
were performed using Chi-square or Fisher’s exact test 
for discrete variables and using the unpaired t test, Wil-
coxon sign-rank test or analysis of variance for continu-
ous variables.
Predictive factors for 90-day mortality were tested in 
univariate and multivariate analyses using a Cox propor-
tional hazards model. The proportional hazards assump-
tion was verified using the Schoenfeld residuals method. 
Variables included in the final multivariable models were 
selected according to their physiological relevance and 
statistical significance in univariate analysis, using a p 
value threshold of 0.10. Two multivariable analyses were 
conducted among cancer patients: the first included 
only variables available on admission: age, comorbid-
ity, performance status, cancer type, metastatic status, 
SAPS 2 and biological data. The second model added in-
ICU management variables (respiratory, circulatory or 
renal support techniques). Analyses were repeated using 
forward stepwise analysis to assess the consistency of 
results. Collinearity was assessed by calculating variance 
inflation factors. In addition, logistic regression was used 
to assess factors predictive of definitive anticancer treat-
ment cessation, and the final model was defined using 
a stepwise method. For all analyses, a p value <0.05 was 
considered statistically significant.
Results
A total of 4185 patients were admitted to the ICU over 
the study period. Of these, 2327 were classified as elderly 
(age ≥65 years), 332 (14.3%) of whom had a solid tumor, 
and 262 (11.3%) were included in the final analysis 
(Fig. 1).
Elderly patients with or without solid tumor
The mean age ± standard deviation of all elderly patients 
(n  =  2327) was 77.1  ±  8.1  years (1311 male; 56.3%). 
Patients with cancer were significantly younger than 
those without cancer (75.2  ±  6.7 vs 79.0  ±  8.2  years; 
p < 0.0001). The mean ± standard deviation IGS2 score in 
all elderly patients was 59.0 ± 23.0. The SAPS 2 score on 
admission was significantly higher in cancer versus non-
cancer patients (61.9 ± 22.5 vs 56.9 ± 22.4; p < 0.0001), as 
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was the McCabe score (2.1 ± 0.6 vs 1.3 ± 0.6; p < 0.025). 
Further details of patient characteristics within the over-
all population are shown in Additional file 1: Table S1.
The ICU mortality for all elderly patients was 32.5% 
and did not differ between those with and without solid 
tumor (33.6 vs 32.7%; p = 0.78). Cancer was not associ-
ated with in-ICU survival (OR for patients without can-
cer 0.96; 95% CI 0.73–1.26; p = 0.78).
Elderly patients with solid tumor
Characteristics
Full details of demographic and clinical characteristics 
for patients with solid tumor are reported in Table  1, 
overall and based on survivorship. Gastrointestinal, 
lung and genitourinary cancers were the most common 
types of tumors (Table 1). Sixty-three percent of patients 
had received at least one previous line of systemic anti-
tumoral treatment (Table  1). Sepsis and acute respira-
tory failure were the two most common reasons for ICU 
admission (Table  2). Based on SAPS 2 score, patients 
were critically ill at admission and 135 (51.5%) required 
mechanical ventilation (Table  2). Median ICU stay was 
4.0 days (interquartile range 2.0–7.0). Laboratory param-
eters for the 262 elderly patients with solid tumors are 
shown in Additional file 1: Table S2.
Outcomes
The ICU mortality rate in elderly solid tumor patients was 
33.6% (n = 88), the in-hospital mortality rate was 43.9% 
(n = 115), while the 90-day mortality was 51.9% (n = 136, 
lost to follow-up n =  14). Out of the 174 patients with 
solid tumor who survived the ICU stay, 28 did not resume 
anticancer therapy because there was no treatment indi-
cation (i.e., localized tumor). Out of the 146 patients with 
advanced disease who theoretically had an indication for 
additional cancer therapy, 77 (52.7%) received treatment, 
54 (37.0%) did not receive treatment, and 15 patients 
(10.3%) were lost to follow-up. Characteristics of the 146 
ICU survivors with anti-tumoral treatment indication are 
presented in Additional file 1: Table S3.
Prognostic factors analysis
Univariate analysis
Variables significantly associated with 90-day death were 
sex (p = 0.03), SAPS 2 score (p < 0.0001), mechanical ven-
tilation (p < 0.0001), inotrope use (p < 0.0001), limitation 
of active therapies during ICU stay (p < 0.0001), primary 
tumor site (p  =  0.005), leukocyte count (p  <  0.0001), 
blood pH (p < 0.0001), lactate levels (p < 0.0001), aspar-
tate aminotransferase level (p  <  0.0001), alanine ami-
notransferase level (p  =  0.01), bilirubin (p  =  0.04) and 
albumin (p = 0.02) (Table 3). Performance status was not 
associated with 90-day mortality in univariate analysis 
(p = 0.07), as was metastatic status (p = 0.82).
Multivariate analysis
High SAPS 2 score (HR 1.05; 95% CI 1.03–1.06, 
p < 0.0001) and primary tumor site (p = 0.01) were sig-
nificantly associated with 90-day death in patients with 
solid tumors admitted in ICU. When artificial life-sup-
port techniques were added to the model, SAPS 2, pri-
mary tumor site, metastatic status and lactates were 
predictive of 90-day death (Additional file  1: Table S4). 
The number and type of previous anticancer therapies 
and the performance status were not associated with 
death in multivariate analysis.
For the 146 patients with an indication for ongo-
ing anticancer therapy, those with a gastrointestinal 
(p = 0.01) or lung (p = 0.02) tumor, or who had a perfor-
mance status of 3 or 4 (p = 0.001) or who were admitted 
in ICU because of cancer progression (p  =  0.04), were 
significantly less likely to have antineoplastic treatment 
restarted after ICU discharge (Table 4).
Discussion
This study provides interesting data about outcomes in 
elderly patients with active solid tumors admitted to the 
ICU, who comprised 14.3% of all elderly patients with an 
Fig. 1 Flow of patients through the study. ICU intensive care unit, 
LATA limitation of active therapies
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ICU admission over the study period (60.3% of these had 
metastatic disease). The presence of a solid tumor did 
not increase ICU mortality compared with patients who 
did not have a solid tumor, but elderly patients admitted 
to the ICU with active cancer were extremely critically 
ill. The majority of indications for ICU admission were 
not related to cancer. More than half of patients with 
an indication for ongoing cancer therapy had treatment 
resumed after their ICU stay. The 90-day mortality was 
51.9%. We identified high SAPS 2 score and primary 
tumor site as being significantly associated with death at 
day 90 on multivariate analysis, whereas previous cancer 
therapies and performance status were not.
In our study, the ICU mortality rate for critically ill 
elderly patients with solid tumors was 33.6%, compara-
ble to that in similar patients without cancer. Previous 
Table 1 Baseline patient demographics and clinical characteristics for the overall study population and by survivor sta-
tus
Data are mean ± SD or number of patients (%)
Overall (n = 262) ICU survivors (n = 174) ICU non-survivors (n = 88) p value
Age (years) 75.2 ± 6.7 75.7 ± 6.8 74.3 ± 6.5 0.13
Male 162 (61.8) 101 (58.0) 61 (69.3) 0.08
Comorbidities
 Tobacco use 106 (40.5) 65 (37.4) 41 (46.6) 0.15
 Diabetes 57 (21.8) 35 (20.1) 22 (25) 0.36
 Chronic respiratory failure 33 (12.6) 23 (13.2) 10 (11.4) 0.18
 Chronic kidney failure 29 (11.1) 23 (13.2) 6 (6.8) 0.12
Primary tumor site 0.02
 Gastrointestinal 71 (27.1) 52 (29.9) 19 (21.6)
 Lung 68 (26) 45 (25.9) 23 (26.1)
 Genitourinary 60 (22.9) 43 (24.7) 17 (19.3)
 Head and neck 31 (11.8) 11 (6.3) 20 (22.7)
 Breast 18 (6.9) 13 (7.5) 5 (5.7)
 Gynecological 9 (3.4) 7 (4) 2 (2.3)
 Sarcoma 3 (1.1) 2 (1.2) 1 (1.1)
 Unknown 2 (0.8) 1 (0.6) 1 (1.1)
Metastasis
 Yes 158 (60.3) 110 (63.2) 48 (54.6) 0.17
 Other 66 (25.3) 42 (24.3) 24 (27.3) 0.58
 Lymph node 58 (22.2) 39 (22.5) 19 (21.6) 0.93
 Lung 57 (21.8) 41 (23.7) 16 (18.2) 0.32
 Bone 46 (17.6) 31 (17.9) 15 (17.1) 0.88
 Liver 38 (14.6) 26 (15) 12 (13.6) 0.78
 Brain 9 (3.5) 6 (3.5) 3 (3.4) 0.73
 Pulmonary lymphangitis 6 (2.3) 4 (2.3) 2 (2.3) 0.67
 Missing 1 (0.4) 1 (0.6) 0 (0)
Anticancer treatment before ICU admission
 Number of previous systemic anti‑tumoral treatments 
[median (IQR)]
1 (0;1) 1 (0;1) 1 (0;1) 0.32
 Missing 8 (3) 5 (2.9) 3 (3.4)
 Chemotherapy 94 (56.3) 66 (60.6) 28 (48.3) 0.18
 Targeted therapy 31 (18.7) 22 (20.2) 9 (15.8)
 Missing 95 (36.3) 65 (37.3) 30 (34)
Performance status
 0 or 1 98 (46.4) 64 (45.7) 34 (47.9) 0.98
 2 86 (40.8) 58 (41.4) 28 (39.4)
 3 or 4 27 (12.9) 18 (12.8) 9 (12.7)
 Missing 51 (19.5) 34 (19.5) 17 (19.3)
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studies assessing the outcome of cancer patients in the 
ICU reported a wide range of mortality rates, from 24 to 
75% [9, 11–15]. This wide range can be explained by the 
marked heterogeneity in patient case mix: medical and 
surgical patients; solid and hematological cancer patients; 
allogeneic and autologous bone marrow transplant recip-
ients; and patients with and without early limitation of 
active therapies [5, 16]. In many studies, hematological 
cancer, medical admissions and limitation of active ther-
apies were associated with worse prognosis [16]. In our 
study, we focused on patients with solid cancers and we 
excluded those with early limitation of active therapies.
To date, few studies in this setting have focused on 
elderly patients. In a registry of 1134 patients aged 
>65 years with advanced lung cancer admitted to ICUs, 
the in-hospital mortality was 33% [8], almost identical to 
the rate in our study. In the registry cohort, age was not 
associated with mortality, and this was also the case in 
multivariate analyses from other studies assessing predic-
tors of death in critically ill patients admitting to the ICU 
with solid cancers [11, 12, 15–17].
In our cohort, patient prognosis after ICU admission 
appeared to be associated more with the severity of clini-
cal condition at ICU admission than with the presence of 
cancer and age, as in most other previous studies [8, 9, 
11–17]. In the Sepsis Occurrence in Acutely Ill Patients 
(SOAP) study, patients with solid tumors had similar sur-
vival to patients without cancer, as was the case in our 
analysis, although the SOAP study included patients aged 
<65 years [18]. Also in the SOAP study, hospital mortality 
Table 2 Baseline patient ICU details for the overall study population and by survivor status
Data are mean ± SD or number of patients (%), expect for time in ICU and in hospital (median and interquartile [IQR]). Time in ICU and in hospital is median (IQR)
Overall (n = 262) ICU survivors (n = 174) ICU non-survivors (n = 88) p value
Reason for ICU admission [n (%)] 0.42
 Not related to cancer 174 (66.4) 120 (68.9) 54 (61.4)
 Related to anticancer drugs 49 (18.7) 29 (16.7) 20 (22.7)
 Related to cancer progression 39 (14.9) 25 (14.4) 14 (15.9)
Reasons for ICU admission [n (%)] <0.001
 Sepsis 80 (30.5) 57 (32.8) 3 (26.1)
 Acute respiratory failure 74 (28.2) 47 (27) 27 (30.8)
 Coma or seizure 21 (8) 12 (6.9) 9 (10.2)
 Cardiorespiratory shock 18 (6.9) 1 (0.5) 17 (19.3)
 Hemorrhagic shock 16 (6.1) 14 (8.1) 2 (2.3)
 Acute kidney failure 14 (5.3) 10 (5.8) 4 (4.6)
 Acute heart failure 10 (3.8) 8 (4.6) 2 (2.3)
 Chronic bronchitis exacerbation 8 (3.1) 7 (4) 1 (1.1)
 Electrolytic disorders 6 (2.3) 5 (2.9) 1 (1.1)
 Hypovolemia 5 (1.9) 4 (2.3) 1 (1.1)
 Intentional overdose 1 (0.4) 1 (0.5) 0 (0)
 Post‑surgery complications 1 (0.4) 1 (0.5) 0 (0)
SAPS 2 score 61.9 ± 22.5 51.4 ± 13.0 82.0 ± 22.9 <0.001
 Neutropenia 19 (7.3) 12 (6.9) 7 (8) 0.75
ICU stay and treatments
 Time in ICU [days, median (IQR)] 4 (2;7) 4 (2;7)0 4 (1;8) 0.26
 Time in hospital [days, median (IQR)] 14 (5;25) 16 (8;27) 6 (2;16) <0.001
 Mechanical ventilation 135 (51.5) 54 (31) 81 (92.1) <0.0001
 Mechanical ventilation duration (days) 3.5 ± 6.3 2.2 ± 4.4 6.2 ± 8.3 <0.001
 Noninvasive ventilation 25 (10.3) 20 (12.9) 5 (5.7) 0.08
 Missing 19 (7.3) 19 (10.9) 0 (0)
 Inotropes 126 (48.3) 52 (30.1) 74 (84.1) <0.0001
 Missing 1 (0.4) 1 (0.6) 0 (0)
 Inotropes duration (days) 1.4 ± 2.4 0.8 ± 1.6 2.7 ± 3.1 <0.001
 Dialysis 33 (12.6) 17 (9.8) 16 (18.2) 0.05
 Missing 1 (0.4) 1 (0.6) 0 (0)
 Limitation of active therapies [n (%)] 46 (17.6) 11 (6.3) 35 (39.8) <0.001
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increased as the number of organs failing increased, and 
more than 75% of the subset of patients with more than 
three failing organs died compared with about 50% of 
patients without cancer (p = 0.01). In a multicenter study 
conducted in Brazil (n = 717), higher Sequential Organ 
Failure Assessment scores were found to be associated 
with increased hospital mortality on multivariate analysis 
(odds ratio [OR] 1.25; 95% confidence interval [CI] 1.17–
1.34) [11].
We found that primary cancer type was associated with 
90-day mortality whereas number of previous cancer 
treatments was not. This is an area of debate, with recent 
studies that assessed factors associated with ICU death in 
cancer patients regardless of age and cancer type show-
ing an inconsistent link between ICU death and cancer 
[5, 9, 16, 19, 20]; some authors have found association 
between cancer progression, metastatic status and prog-
nosis [9, 11, 15]. In a large multicenter study including 717 
Table 3 Independent predictors of 90-day mortality in elderly solid tumor patients (n = 262)
ASAT aspartate aminotransferase, CI confidence interval, HR hazard ratio
Univariate Multivariate
HR (95% CI) p value HR (95% CI) p value
Age (HR for increase of 1 year) 0.98 (0.95–1.01) 0.16 0.99 (0.95–1.03) 0.57
Sex
 Male 1 1
 Female 0.66 (0.46–0.96) 0.03 0.75 (0.43–1.30) 0.30
Performance status
 0–1 1 0.07 1 0.17
 2 1.30 (0.85–1.97) 1.58 (0.97–2.59)
 3–4 1.88 (1.10–3.23) 1.53 (0.77–3.05)
Primary tumor site
 Genitourinary 1 0.005 1 0.01
 Gastrointestinal 1.10 (0.65–1.86) 0.96 (0.49–1.89)
 Breast 0.82 (0.36–1.89) 0.38 (0.11–1.27)
 Lung 1.37 (0.83–2.26) 1.11 (0.59–2.08)
 Head and neck 2.60 (1.49–4.53) 2.69 (1.25–5.79)
 Other 0.75 (0.29–1.96) 0.80 (0.24–2.67)
Metastatic status
 No 1 1
 Yes 0.96 (0.68–1.36) 0.82 1.61 (0.98–2.59) 0.06
Number of previous systemic anti‑tumoral treatments 0.88 (0.73–1.07) 0.19 (–)
Reason for ICU admission
 Not related to cancer 1 (–) 0.68 1 0.50
 Related to anticancer drugs 1.07 (0.69–1.67) 0.87 (0.49–1.52)
 Related to cancer progression 1.23 (0.76–2.00) 1.23 (0.66–2.28)
SAPS 2 score (HR for increase of 1 unit) 1.05 (1.04–1.06) <0.0001 1.05 (1.03–1.06) <0.0001
Life‑support techniques
 Mechanical ventilation use 5.96 (3.91–9.10) <0.0001 (–)
 Noninvasive ventilation use 0.81 (0.46–1.44) 0.48 (–)
 Inotropes use 3.68 (2.54–5.33) <0.0001 (–)
 Dialysis use 1.28 (0.79–2.08) 0.32 (–)
Limitation of active therapies during ICU stay 3.79 (2.59–5.56) <0.0001 (–)
Laboratory findings (HR for increase of 1 unit)
 Albumin 0.94 (0.89–0.99) 0.02 (–)
 Leukocytes 1.01 (1.01–1.02) <0.0001 0.99 (0.97–1.01) 0.57
 Glycemia 1.03 (1.00–1.05) 0.04 1.01 (0.98–1.06) 0.46
 pH 0.04 (0.01–0.13) <0.0001 0.85 (0.16–4.41) 0.84
 Lactates 1.18 (1.13–1.22) <0.0001 1.07 (0.99–1.15) 0.08
 ASAT 1 (1–1.001) <0.0001 1 (1–1) 0.58
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patients (667 with solid tumors and 50 with hematologi-
cal malignancies), active recurrent or progressive malig-
nancy was associated with increased hospital mortality 
in multivariate analysis [11, 17]. Another study among 
patients with solid tumors (n = 162) found that complete 
or partial remission of the underlying cancer decreased 
the risk of ICU mortality (OR 0.026, 95% CI 0.002–0.3; 
p  =  0.004) [15]. Our data showed that ICU admission 
related to tumor progression was not associated with 
mortality, but was associated with less resumption of anti-
cancer treatment. However, we did exclude patients with 
early limitation of active therapies, and most admissions 
were not related to cancer progression. It has previously 
been shown that some specific causes of admission due to 
progression of solid tumors are associated with very poor 
prognosis [21, 22]. As a result, the elderly patients admit-
ted to the ICU in this study might represent a selected 
group, and we did not assess patients not referred to the 
ICU by the oncologist or refused by the intensivist.
There is a relative lack of data about links between 
long-term outcome and anticancer therapy resump-
tion [8, 9]. In our study, the number of patients able to 
resume antineoplastic therapy was encouraging (52.7%). 
This rate is high compared to the small amount of exist-
ing data. In one study of 1134 patients aged >65  years 
with active advanced lung cancer, only 19% resumed 
anticancer therapy after ICU discharge [8]. Another 
study about critically ill lung cancer patients reported 
a therapy resumption rate of 37% [9]. Possible reasons 
for the lower rates in the other studies could be the 
advanced stage of lung cancer, the high proportion of 
cancer-related complications and low number of thera-
peutic options in those patients. In addition, new tar-
geted therapies in oncology and the fact that our cohort 
included other tumor types could have contributed to the 
different results between studies. It has been previously 
reported that there is a link between poor performance 
status and no resumption of anticancer treatment after 
an ICU stay [9]. Similarly, we found that gastrointestinal 
and lung cancer or patient admitted to the ICU because 
of tumor progression, or with poor performance status 
were prognostic factors for no anticancer therapy after 
ICU discharge. One explanation for this could be that 
patients with tumor progression may be more weakened 
by an ICU stay, and thus, further cancer therapy might be 
deemed too intense for them.
This study had several strengths. It is one of the largest 
cohorts in which long-term mortality of elderly patients 
with active cancer admitted to the ICU has been deter-
mined. Moreover, only patients with solid tumors were 
included, eliminating high-risk populations (e.g., patients 
with hematological malignancies. Another strength was 
the collection of data about tumor and metastatic sites, 
as well as the number and type of treatments received 
prior to ICU admission. Furthermore, we include data 
on resumption of anticancer therapy after ICU discharge, 
something that has only been reported in a few previous 
studies and is clinically relevant because it could play a 
part in assessing whether or not to admit a patient with 
cancer to the ICU.
Our study also has some limitations that need to be 
taken into account when interpreting the data. The study 
was conducted in a single center and had a retrospec-
tive design. Also, there were some database limitations, 
including missing data on biological and clinical variables 
(e.g., albumin level or performance status) meaning that 
calculations on the prognostic value of these variables 
may be affected. Furthermore, our results are only appli-
cable to a subset of similar patients due to selection bias; 
patients too unwell to be admitted to the ICU were not 
included, as indicated by the fact that only 15% of our 
patients were in the ICU because of cancer progression. 
As a result, the study population had a relatively better 
general condition with fewer comorbidities, which may 
explain the good outcomes observed.
Conclusions
Our study results showed that elderly patients 
(≥65  years) with solid tumor admitted to the ICU had 
the same mortality rate as similar elderly patients without 
Table 4 Multivariate analysis of  factors associated 
with  definitive anticancer drug cessation after  ICU dis-
charge in survivors
CI confidence interval, OR odds ratio, LAT limitation of active therapies
OR 95% CI p value
Primary tumor site
 Genitourinary 1
 Gastrointestinal 8.70 1.61–47.15 0.01
 Lung 6.92 1.28–37.38 0.02
 Breast 1.41 0.10–20.17 0.80
 Other 5.50 0.71–42.68 0.10
Performance status
 0 or 1 1
 2 2.26 0.82–7.60 0.14
 3 or 4 14.96 2.71–78.68 0.001
Reason for ICU admission
 Not related to cancer 1
 Related to anticancer drugs 1.10 0.76–6.69 0.87
 Related to cancer progression 4.19 1.03–17.14 0.04
Other
 LAT in ICU 191,146,845.57 0–Inf 0.99
 Dialysis 3.19 0.67–15.28 0.14
 High blood bilirubin level 1.00 0.99–1.02 0.48
Page 8 of 8Auclin et al. Ann. Intensive Care  (2017) 7:26 
cancer. In addition, more than half of the elderly cancer 
patients discharged from the ICU were able to resume 
anticancer treatment. Factors associated with ICU mor-
tality were related to the patients’ status at ICU admis-
sion and not to the presence of metastatic disease or 
the number of previous anticancer treatments. These 
findings suggest that early admission of elderly cancer 
patients to the ICU is appropriate, when necessary.
Abbreviations
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